相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A practical guide to cancer subclonal reconstruction from DNA sequencing
Maxime Tarabichi et al.
NATURE METHODS (2021)
MIAmS: microsatellite instability detection on NGS amplicons data
Frederic Escudie et al.
BIOINFORMATICS (2020)
Germline genetic testing for breast cancer: which patients? What genes?
Susan M. Domchek
GENETICS IN MEDICINE (2020)
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
Pan-cancer analysis of whole genomes
Peter J. Campbell et al.
NATURE (2020)
The repertoire of mutational signatures in human cancer
Ludmil B. Alexandrov et al.
NATURE (2020)
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)
Marilyn M. Li et al.
GENETICS IN MEDICINE (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer
Alex H. Wagner et al.
NATURE GENETICS (2020)
Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer
Aphrothiti J. Hanrahan et al.
CANCER RESEARCH (2020)
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
Julie N. Graff et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)
L. J. Wirth et al.
ANNALS OF ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
How current assay approval policies are leading to unintended imprecision medicine
Roberto Salgado et al.
LANCET ONCOLOGY (2020)
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Qiang Li et al.
CLINICAL CANCER RESEARCH (2019)
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid
Alexandra M. Miller et al.
NATURE (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology
Roberto Salgado et al.
EUROPEAN JOURNAL OF CANCER (2019)
Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab (vol 71, pg 433, 2019)
Peter A. Johansson et al.
IMMUNOGENETICS (2019)
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
Emil Christensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
Daniel A. Pollyea et al.
LEUKEMIA (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
Thomas Reinert et al.
JAMA ONCOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features
Remi Buisson et al.
SCIENCE (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Johan Staaf et al.
NATURE MEDICINE (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA93Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
L Wirth et al.
ANNALS OF ONCOLOGY (2019)
1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
A Marabelle et al.
ANNALS OF ONCOLOGY (2019)
Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
A. Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Pedram Razavi et al.
NATURE MEDICINE (2019)
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Neil Vasan et al.
SCIENCE (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
Wassim Abida et al.
JAMA ONCOLOGY (2019)
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology
Jessica J. Tao et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Comprehensive Characterization of Cancer Driver Genes and Mutations
Matthew H. Bailey et al.
CELL (2018)
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu et al.
CELL (2018)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project
Pauline Robbe et al.
GENETICS IN MEDICINE (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
DKK2 imparts tumor immunity evasion through beta-catenin-independent suppression of cytotoxic immune-cell activation
Qian Xiao et al.
NATURE MEDICINE (2018)
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
Seung Tae Kim et al.
NATURE MEDICINE (2018)
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
Manuel Rodrigues et al.
NATURE COMMUNICATIONS (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
David Tamborero et al.
GENOME MEDICINE (2018)
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
Ryan N. Ptashkin et al.
JAMA ONCOLOGY (2018)
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study
Eli L. Diamond et al.
JAMA ONCOLOGY (2018)
Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program
Andrea Eisen et al.
MOLECULAR GENETICS & GENOMIC MEDICINE (2018)
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
J. Mateo et al.
ANNALS OF ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Craig M. Bielski et al.
CANCER CELL (2018)
Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
Jacqueline A. Shaw et al.
CLINICAL CANCER RESEARCH (2017)
The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations
Linda Huang et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2017)
Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer
Allison W. Kurian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer The SELECT-1 Randomized Clinical Trial
Pasi A. Janne et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
Diana Mandelker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Solange Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
AKT Inhibition in Solid Tumors With AKT1 Mutations
David M. Hyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Hatim Husain et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Integrative clinical genomics of metastatic cancer
Dan R. Robinson et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes
Yi Kan Wang et al.
NATURE GENETICS (2017)
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
Malachi Griffith et al.
NATURE GENETICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Janet Woodcock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA methylation markers for diagnosis and prognosis of common cancers
Xiaoke Hao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy SWOG S1115 Study Randomized Clinical Trial
Vincent Chung et al.
JAMA ONCOLOGY (2017)
Oncologist use and perception of large panel next-generation tumor sequencing
A. M. Schram et al.
ANNALS OF ONCOLOGY (2017)
Evaluating somatic tumor mutation detection without matched normal samples
Jamie K. Teer et al.
HUMAN GENOMICS (2017)
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes
Catherine C. Coombs et al.
CELL STEM CELL (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
K. Haratani et al.
ANNALS OF ONCOLOGY (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
Matthew T. Chang et al.
NATURE BIOTECHNOLOGY (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The precision-oncology illusion
Vinay Prasad
NATURE (2016)
Genomic evolution and chemoresistance in germ-cell tumours
Amaro Taylor-Weiner et al.
NATURE (2016)
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing
Ronglai Shen et al.
NUCLEIC ACIDS RESEARCH (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: Implications for precision cancer medicine
Eliezer M. Van Allen et al.
ONCOTARGET (2016)
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
Andrea Garofalo et al.
GENOME MEDICINE (2016)
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
Tracy L. Stockley et al.
GENOME MEDICINE (2016)
Somatic cancer variant curation and harmonization through consensus minimum variant level data
Deborah I. Ritter et al.
GENOME MEDICINE (2016)
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Kasmintan A. Schrader et al.
JAMA ONCOLOGY (2016)
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Adult Subjects with NTRK Fusion-Positive Tumors.
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies
Sara E. Patterson et al.
HUMAN GENOMICS (2016)
A survey of best practices for RNA-seq data analysis
Ana Conesa et al.
GENOME BIOLOGY (2016)
f Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl et al.
JCI INSIGHT (2016)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy
Sander Kelderman et al.
CANCER CELL (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing
Marcin Cieslik et al.
GENOME RESEARCH (2015)
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Amanda J. Redig et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Germline Mutations in Predisposition Genes in Pediatric Cancer
Jinghui Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
HER2 missense mutations have distinct effects on oncogenic signaling and migration
Daniel J. Zabransky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Personalized genomic analyses for cancer mutation discovery and interpretation
Sian Jones et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
MSIseq: Software for Assessing Microsatellite Instability from Catalogs of Somatic Mutations
Mi Ni Huang et al.
SCIENTIFIC REPORTS (2015)
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies
Jeffrey S. Ross et al.
JAMA ONCOLOGY (2015)
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Beifang Niu et al.
BIOINFORMATICS (2014)
Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
Lydia W. T. Cheung et al.
CANCER CELL (2014)
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Moriah H. Nissan et al.
CANCER RESEARCH (2014)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
Katherine A. Hoadley et al.
CELL (2014)
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2014)
FDA Perspective on Companion Diagnostics: An Evolving Paradigm
Elizabeth A. Mansfield
CLINICAL CANCER RESEARCH (2014)
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
Ludmil B. Alexandrov et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2014)
Attitudes and knowledge of medical practitioners to hereditary cancer clinics and cancer genetic testing
Ian Teng et al.
FAMILIAL CANCER (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Physicians' Attitudes About Multiplex Tumor Genomic Testing
Stacy W. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
Laura E. MacConaill et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2014)
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features
Yunjian Pan et al.
LUNG CANCER (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
Eliezer M. Van Allen et al.
NATURE MEDICINE (2014)
Anchored multiplex FOR for targeted next-generation sequencing
Zongli Zheng et al.
NATURE MEDICINE (2014)
The Race to Clone BRCA1
Mary-Claire King
SCIENCE (2014)
BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells By Reactivating MEK and ERK Signaling
Berta Sanchez-Laorden et al.
SCIENCE SIGNALING (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
Dan A. Landau et al.
CELL (2013)
Ethical, Legal, and Counseling Challenges Surrounding the Return of Genetic Results in Oncology
Martijn P. Lolkema et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Muhammed Murtaza et al.
NATURE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed
Howard L. McLeod
SCIENCE (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel
Daniel L. Hertz et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Ramaswamy Govindan et al.
CELL (2012)
Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
Kurtis D. Davies et al.
CLINICAL CANCER RESEARCH (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Koichi Goto et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Targeting ALK in neuroblastoma-preclinical and clinical advancements
Erica L. Carpenter et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Margaret K. Callahan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
William J. Irvin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non-Small-Cell Lung Cancer
Zengliu Su et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2011)
Genomic Medicine Genomics and Drug Response
Liewei Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Detection and quantification of rare mutations with massively parallel sequencing
Isaac Kinde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Lydia W. T. Cheung et al.
CANCER DISCOVERY (2011)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
US system of oversight for genetic testing: a report from the Secretary's Advisory Committee on Genetics, Health and Society
Andrea Ferreira-Gonzalez et al.
PERSONALIZED MEDICINE (2008)
Urinary cell-free DNA as a potential tumor marker for bladder cancer
H. W. Chang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
Takeshi Shimamura et al.
CANCER RESEARCH (2006)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Intragenic ERBB2 kinase mutations in tumours
P Stephens et al.
NATURE (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Nonsense-mediated decay approaches the clinic
JA Holbrook et al.
NATURE GENETICS (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis
T Lecomte et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
The fundamental role of epigenetic events in cancer
PA Jones et al.
NATURE REVIEWS GENETICS (2002)
Oncologists' opinions on genetic testing for breast and ovarian cancer
JO Culver et al.
GENETICS IN MEDICINE (2001)
分享论文
